Alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR)

The **alpha-3 beta-4 nicotinic acetylcholine receptor** is a heteropentameric ligand-gated ion channel composed of α3 and β4 subunits, predominantly expressed in the autonomic ganglia and adrenal medulla[1][6]. These receptors mediate fast synaptic transmission by increasing membrane permeability to Na^+, K^+, and Ca^2+, resulting in neuronal excitation. The α3β4 receptor plays a key role in autonomic regulation and synaptic signaling from the central nervous system to peripheral organs. In the brain, it participates in the neural reward circuitry and has been implicated in the physiology and pathology of drug addiction—making it a promising therapeutic target for smoking cessation and addiction-related conditions[2][4][5][6]. Detailed structural studies have clarified its ligand-binding properties, gating, and ion permeation mechanisms[1][3]. A range of drugs, both agonists and antagonists, interact with this receptor. Selective antagonists such as AT-1001 demonstrate its potential for pharmacological intervention with reduced side effects relative to non-specific nAChR blockers[2][4][5]. Recent work suggests α3β4 receptor levels may serve as biomarkers for addiction risk and treatment response[8]. Safety concerns center on the need for high subtype selectivity to avoid unwanted systemic autonomic effects[5][6].

Other names

α3β4 receptorα3β4 nicotinic receptorGanglion-type nicotinic receptor

Drugs may act as **agonists**, stimulating the receptor and causing cation (Na^+, K^+, Ca^2+) influx and neuronal depolarization[1][3][6]. - **Antagonists** (such as AT-1001, mecamylamine, hexamethonium, DHβE) can block receptor activation and disrupt neurotransmission[2][4][5]. - Some antagonists work **competitively** (binding at the acetylcholine binding site), while others act **noncompetitively** (allosteric modulation or channel block)[5][6].